Role of the informed consent, from mesotherapy to opioid therapy

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 4, 2014, Pages 566-574

  Mammucari, M ^a   Lazzari, M ^b   Maggiori, E ^a   Gafforio, P ^b   Tufaro, G ^b   Baffini, S ^a   Maggiori, S ^a   Palombo, E ^b   De Meo, B ^b   Sabato, A F ^b  

^a Italian Society of Mesotherapy   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Informed consent; Mesotherapy; Opioid therapy

Indexed keywords

KETOPROFEN; NARCOTIC ANALGESIC AGENT; THALIDOMIDE;

ARTICLE; CHRONIC PAIN; CLINICAL PRACTICE; DOCTOR PATIENT RELATION; HUMAN; INFORMED CONSENT; JURISPRUDENCE; MESOTHERAPY; PATIENT DECISION MAKING; TREATMENT RESPONSE; ADVERSE EFFECTS; ATTITUDE TO HEALTH; HEALTH PERSONNEL ATTITUDE; INTERPERSONAL COMMUNICATION; PATIENT; PATIENT EDUCATION; PATIENT PARTICIPATION; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR;

ANALGESICS, OPIOID; ATTITUDE OF HEALTH PERSONNEL; COMMUNICATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMED CONSENT; MESOTHERAPY; PATIENT EDUCATION AS TOPIC; PATIENT PARTICIPATION; PATIENTS; PHYSICIAN-PATIENT RELATIONS; RISK ASSESSMENT; RISK FACTORS;

EID: 84897002303     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. MALLARDI V. The origin of informed consent. Acta Otorhinol Ital 2005; 25: 312-327.
2. SEIDELMAN WE. Nuremberg lamentation: for the forgotten victims of medical science. Br Med J 1996; 313: 1463-1467.
3. MARRUS MR. The Nuremberg Doctors' Trial in historical context. Bull Hist Med 1999; 73: 106-123.
4. NUREMBERG MILITARY TRIBUNAL. Permissible medical experiment (known as The Nuremberg Code). In: Trials of war criminals before the Nuremberg Military Tribunals under Control Council Law no. 10. Nuremberg, October 1946-April 1949. Washington, DC: Government Printing Office; 1949-1953; 2: pp. 181-182.
5. URL:http://www.cirp.org/library/ethics/geneva
6. http://www.wma.net/en/30publications/10policies/g1
7. MCBRIDE WG. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358.
8. LENZ W. Thalidomide and congenital anomalies. Lancet 1962; 1: 45.
9. LENZ W, KNAPP K. Foetal malformations due to thalidomide. Ger Med Mthly 1962; 7: 253-258.
10. RICKHAM PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J 1964; 2(5402): 177.
11. HUMAN D, CRAWLEY F, IJESSELMUIDEN C. Revised declaration of Helsinki. WMA will continue to revise policy as medicine and research changes. Br Med J 2001; 323: 283-284.
12. GELLER SE, PATEL A, NIAK VA, GOUDAR SS, EDLAVITCH SA, KODKANY BS, DERMAN RJ. Conducting international collaborative research in developing nations. Int J Gynaecol Obstet 2004; 87: 267-271.
13. RESEARCH IN DEVELOPING COUNTRIES. Bull Med Ethics 2005; (208): 7-11.
14. PETRINI C. Informed consent in experimentation involving mentally impared person: ethical issues. Ann Ist Super Sanita 2010; 46: 411-421.
15. PETRINI C. Informed consent from cognitively impaired persons participating in research trials: comparative law observations. Ann Ist Super Sanita 2011; 47: 353-362.
16. BLACKMER J. The ethical obligations of researchers in protecting the rights of human research subjects. World Med Health Policy. 2010; 2: 91-96.
17. SLATER V. Baker and Stapleton, 95 Eng. Rep. 860, 2 Wils K.I. (1767).
18. CAPENTER V Blake, 60 Barb. N.Y. 488 (1871).
19. MOHR V.Williams (104 N.W. 12) (1905).
20. SCHLOENDORFF V. Society of New York Hosp. 211 N.Y. 125. 105 N.E. 92 (1914).
21. SALGO V Leland Stanford etc. Bd. Trustees, 154 Cal. App. 2d 560 (Civ. No. 17045. First Dist., Div. One. Oct. 22, 1957).
22. CANTERBURY V. Spence. 464 F. 2d 772. 787 (D.C. Cir.). cert. denied. 409 U.S. 1064 (1972).
23. DEMERS V. Gerety 85 N.M. 641, 515 P. 2d 645 (Ct. App. 1973).
24. SPRUNG CL, WINICK BJ. Informed consent in theory and practice: legal and medical perspectives on the informed consent doctrine and a proposed reconceptualization. Crit Care Med 1989; 17: 1346-1354.
25. GIAMPIERI M. Communication and informed consent in elderly people. Minerva Anestesiol 2012; 78: 236-242.
26. BROPHY E. Does a doctor have a duty to provide information and advice about complementary and alternative medicine? J Law Med 2003; 10: 271-284.
27. ERNST E. Complementary medicine: implications for informed consent in general practice. Br J Gen Pract 2004; 54: 82-83.
28. HUSSAIN MS. Patient counseling about herbal-drug interactions. Afr J Tradit Complement Altern Med 2011; 8: 152-163.
29. IZZO AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2005; 19: 1-16.
30. SANDERSON CR, KOCZWARA B, CURROW DC. The "therapeutic footprint" of medical, complementary and alternative therapies and a doctor's duty of care. Med J Aust 2006; 185: 373-376.
31. PISTOR M. What is mesotherapy?. Chir Dent Fr 1976; 46: 59-60.
32. DALLOZ-BOURGUIGNON A. A new therapy against pain: mesotherapy. J Belge Med Phys Rehabil 1979; 2: 230-234.
33. MAGGIORI S. Manuale di Intradermoterapia Distrettuale. La Mesoterapia in Italia, EMSI, Roma, Italy, 2004.
34. ROHRICH RJ. Mesotherapy: what is it? Does it work? Plastic Reconstr Surg 2005; 115: 1425, 2005.
35. MAMMUCARI M, GATTI A, MAGGIORI S, BARTOLETTI CA, SABATO AF. Mesotherapy, definition, rationale and clinical role: a consensus report from the italian society of mesotherapy. Eur Rev Med Pharmacol Sci 2011; 15: 682-694.
36. MAMMUCARI M, GATTI A, MAGGIORI S, SABATO AF. Role of Mesotherapy in musculoskeletal pain: opinion from the italiana socity of mesotherapy. Evid Based Complement Alternat Med 2012; 2012: 436959.
37. HERREROS FOC, DE MORAES AM, VELHO PENF. Mesotherapy: a bibliographical review. Anais Brasileiros de Dermatologia 2011; 86: 96-101.
38. PEZONE A, MARTINI D, IACONO M. Mesotherapy in the treatment of debsores in spinal patients. J Mesother 1981; 1: 67-69.
39. GALLO R. Mesotherapy in phlebology. Phlebologie 1980; 33: 153-156.
40. TOMASELLI F, SCONDOTTO G, SFORZA G. First data on the use of mesotherapy controlled in the treatment of phlebolymphedemas. J Mesother 1981; 1: 71-76.
41. MAGGIORI E, BARTOLETTI CA, MAGGIORI S, TOMASELLI F, DORATO D. Local intradermotherapy (ITD) with mesoglican in PEFS and CVLI, retrospective study. Trends Med 2010; 10: 73-78.
42. MANTOUX C. L'intradermoréaction a la tuberculine et son interpretation clinique. Presse Med 1910; 18: 10-13.
43. TUFT L. Active immunization against typhoid fever, with par ticular reference to an intradermal method. J Lab Clin Med 1931; 16: 552-556.
44. PITZURRA M, MARCONI P. Immunogenesis and mesotherapy: the immunoresponse to antigens inoculated intradermally. J Mesother 1981; 1: 9-14.
45. COUDEVILLE L, ANDRE P, BAILLEUX F. WEBER F, PLOTKIN S. A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes. HumVaccin 2010; 6: 841-848.
46. STICCHI L, ALBERTI M, ALICINO C, CROVARI P. The intradermal vaccination: past experiences and current perspectives. J Prev Med Hyg 2010; 51: 17-14.
47. MERLEN JF, CURRI SB, SARTEEL AM. Cellulitis, a conjunctive microvascular disease. Phlebologie 1979; 32: 279-282.
48. MERLEN JF. Physiopathology of sclerosis cellulites. Phlebologie 1981; 34: 537-541.
49. BARTOLETTI CA, GUALTIEROTTI R, TOMASELLI F. Mesotherapy and gel frigotherapy in the treatment of "cellulitis" and phlebolymphoedemas in the lower limbs. J Mesother 1981; 1: 127-138.
50. LACARRUBA F, TEDESCHI A, NARDONE B, MICALI G. Mesotherapy for skin rejuvenation: assessment of the subepidermal low-echogenic band by ultrasound evaluation with cross-sectional B-mode scanning. Derm Ther 2008; 21: 1-5.
51. MAGGIORI E, BARTOLETTI E, MAMMUCARI M. Intradermal therapy (mesotherapy) with lymdiaral in chronic venous insufficiency with associated fibrosclerotic edema damage: a pilot study. J Altern Complement Med 2013; 19: 777-781.
52. OGDEN S, GRIFFITHS TW. A review of minimally invasive cosmetic procedures. Br J Dermatol 2008; 159: 1036-1050.
53. CARRUTHERS JD, GLOGAU RG, BLITZER A. Facial Aesthetics Consensus Group Faculty Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies consensus recommendations. Plast Reconstr Surg 2008; 121: 5-30.
54. SMALL R. Aesthetic procedures in office practice. Am Fam Physician 2009; 80: 1231-1237.
55. URBANI CE. Urticarial reaction to ethylenediamine in aminophylline following mesotherapy. Contact Dermatitis 1994; 31: 198-199.
56. NAGORE E, RAMOS P, BOTELLA-ESTRADA R. Cutaneous infection with Mycobacterium fortuitum after localized microinjections (mesotherapy) treated successfully with a triple drug regimen. Acta Derm Venereol 2001; 81: 291-293.
57. TAN J, RAO B. Mesotherapy-induced panniculitis treated with dapsone: case report and review of reported adverse effects of mesotherapy. J Cutan Med Surg 2006; 10: 92-95.
58. VIANA-NIERO C, LIMA KV, LOPES ML, ST AL. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol 2008; 46: 850-855.
59. CARBONNE A, BROSSIER F, ARNAUD I, BOUGMIZA I, CAUMES E, MENINGAUD JP, DUBROU S, JARLIER V, CAMBAU E, ASTAGNEAU P. Outbreak of non-tuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol 2009; 47: 1961-1964.
60. YAAR R, GARG A, AL-DAWARI N, GOLDBERG L. Delayed idiosyncratic inflammatory reaction to cosmetic injection of vitamin E. J Cutan Pathol 2009; 36: 137.
61. NABAVI CB, MINCKLER DS, TAO JP. Histologic features of mesotherapy-induced orbital fat inflammation. Ophthal Plast Reconstr Surg 2009; 25: 69-70.
62. DEL-CASTILLO M, PALMERO D, LOPEZ B, PAUL R, RITACCO V, BONVEHI P, CLARA L, AMBROGGI M, BARRERA L, VAY C. Mesotherapy-associated outbreak caused by Mycobacterium immunogenum. Emerg Infect Dis 2009; 15: 357-359.
63. KIM JB; MOON W, PARK SJ, KIM KJ, LEE JN, KANG AJ, JANG LL, CHANG HK. Ischemic colitis after mesotherapy combined with anti-obesity medications. World J Gastroenterol 2010; 16: 1537-1540.
64. CORREA NE, CATANO JC, MEJIA GI, REALPE T. Outbreak of mesotherapy-associated cutaneous infections caused by mycobacterium chelonae in Colombia. J Infect Dis 2010; 63: 143-145.
65. ORJUELA D, PUERTO G, MEJÍA G, CASTRO C, GARZÓN MC, GARCÍA LM, HERNÁNDEZ E, RIBÓN W, RODRÍGUEZ G. Cutaneous tuberculosis after mesotherapy: report of six cases. Biomedica. 2010; 30(3): 321-326.
66. BROOKS JH, CRIEP LH, RUBEN FL. Intradermal administration of bivalent and monovalent influenza vaccines. Ann Allergy 1977; 39:110-112.
67. HALPERIN W, WEISS WI, ALTMAN R, DIAMOND MA, BLACK KJ, IACI AW, BLACK HC, GOLDFIELD M. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/(swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979; 69: 1247-1251.
68. BELSHE RB, NEWMAN FK, CANNON J, DUANE C, TREANOR J, VAN HOECKE C, HOWE BJ, DUBIN G. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351: 2286-2294.
69. ALARCON JB, HARTLEY AW, HARVEY NG, MIKSZTA JA. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol 2007; 14: 375-381.
70. KENNEY RT, FRECH SA, MUENZ LR, VILLAR CP, GLENN GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351: 2295-2301.
71. NICOLAS JF, GUY B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7: 1201-1214.
72. HOLLAND D, BOOY R, DE LF, EIZENBERG P, MCDONALD J, KARRASCH J, MCKEIRNAN M, SALEM H, MILLS G, REID J, WEBER F, SAVILLE M. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198: 650-658.
73. VERWEIJ MF, VAN DEN HOVEN MA. Influenza vaccination in Dutch nursing homes: is tacit consent morally justified? Med Health Care Philos 2005; 8: 89-95.
74. DIAMOND MR, O'BRIEN-MALONE A. Vaccination, consent and multidose vials. Med J Aust 2011; 194: 414-416.
75. CHEVAT C, VIALA-DANTEN M, DIAS-BARBOSA C, NGUYEN VH. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the Vaccinees' Perception of Injection (VAPI) questionnaire. Health Qual Life Outcomes 2009; 7: 21.
76. NICOLAIDES AN, ALLEGRA C, BERGAN J, BRADBURY A, CAIROLS M, CARPENTIER P, COMEROTA A, DELIS C, EKLOF B, FASSIADIS N, GEORGIOU N, GEROULAKOS G, HOFFMANN U, JANTET G, JAWIEN A, KAKKOS S, KALODIKI E, LABROPOULOS N, NEGLEN P, PAPPAS P, PARTSCH H, PERRIN M, RABE E, RAMELET AA, VAYSSAIRA M, IOANNIDOU E, TAFT A. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol 2008; 27: 1-59.
77. GLOVICZKI P, COMEROTA AJ, DALSING MC, EKLOF BG, GILLESPIE DL, GLOVICZKI ML, LOHR JM, MCLAFFERTY RB, MEISSNER MH, MURAD MH, PADBERG FT, PAPPAS PJ, PASSMAN MA, RAFFETTO JD, VASQUEZ MA, WAKEFIELD TW; SOCIETY FOR VASCULAR SURGERY; AMERICAN VENOUS FORUM. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2011; 53: 2S-48S.
78. HONIGMAN R, CASTLE DJ. Aging and cosmetic enhancement. Clin Interv Aging 2006; 1: 115-119.
79. BERRIOS GE, KAN CS. A conceptual and quantitative analysis of 178 historical cases of dysmorphophobia. Acta Psychiatr Scand 1996; 94: 1-7.
80. SITUM M, BULJAN M. How to protect medical professionals from unrealistic expectations of clients in corrective dermatology? Acta Clin Croat 2010; 49: 509-513.
81. CHEATLE MD, SAVAGE SR. Informed consent in opioid therapy: a potential obligation and opportunity. J Pain Symptom Manage 2012; 44: 105-116.
82. GUIDELINES AIOM 2012 "Terapia del dolore in oncologia" available at http://www.aiom.it/area+pubblica/area+medica/prodotti+scientifici/ linee+guida/1%2C333%2C1%2C
83. RIPAMONTI CI, SANTINI D, MARANZANO E, BERTI M, ROILA F; ESMO GUIDELINES WORKING GROUP. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23: vii139-154.
84. AMBROSIO F, FINCO G, MATTIA C, MEDIATI R, PAOLETTI F, COLUZZI F, PIACEVOLI Q, SAVOIA G, AMANTEA B, AURILIO C, BONEZZI C, CAMAIONI D, CHIEFARI M, COSTANTINI A, EVANGELISTA M, ISCHIA S, MONDELLO E, POLATI E, RAFFAELI W, SABATO AF, VARRASSI G, VISENTIN M, TUFANO R; SIAARTI CHRONIC NON-CANCER PAIN STUDY GROUP. SIAARTI recommendations for chronic noncancer pain. Minerva Anestesiol 2006; 72: 859-880.
85. CARACENI A, HANKS G, KAASA S. Use of opioid analgesics in the treatment of cancer pain: evidencebased recommendations from the EAPC. Lancet Oncol 2012; 13: e58-e68
86. WHO. Cancer pain relief. 2nd edn. Geneva;World Health Organization, 1996.
87. DEANDREA S, MONTANARI M, MOJA L, APOLONE G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19: 1985-1991.
88. BENNETT DS, CARR DB. Opiophobia as a barrier to the treatment of pain. J Pain Palliat Care Pharmacother 2002; 16: 105-109.
89. AMERICAN ACADEMY OF PAIN MANAGEMENT. Opioid Agreements and Contracts available at http://www.naddi.org/aws/NADDI/pt/sp/resources-pain-management
90. SAVIGNY P, WATSON P, UNDERWOOD M; GUIDELINE DEVELOPMENT GROUp. Early management of persistent non-specific low back pain: summary of NICE guidance. Br Med J 2009; 338: b1805.
91. BELL K, SALMON A. Pain, physical dependence and pseudoaddiction: redefining addiction for 'nice' people? Int J Drug Policy 2009; 20: 170-178.
92. BASHAYREH A. Opioidphobia and cancer pain management. J Pediatr Hematol Oncol 2011; 33(1): S60eS61.
93. RIPAMONTI C, VALLE A, PERUSELLI C, PESSI MA, PRANDI C. Project "Hospital without pain": analysis of the Italian situation before the law 38. Assist Inferm Ric 2011; 30: 95-99.
94. MURINO P, MAMMUCARI M, BORRELLI D, PEPE A, GIUGLIANO MF, MORRA A, PANELLI G, MANZO R, RAVO V, MUTO P. Role of immediate-release morphine (MIR) in the treatment of predictable pain in radiotherapy. J Pain Palliat Care Pharmacother 2011; 5: 121-124.
95. AMERICAN MEDICAL ASSOCIATION. Patient physician relationship topics. Informed consent. http://www.ama-assn.org/ama/pub/physicianresources/legal- topics/patient-physicianrelationship-topics/informed-consent.page?
96. FEDERATION OF STATE MEDICAL BOARDS OF THE UNITED STATES, INC. Model policy for the use of controlled substances for the treatment of pain. J Pain Palliat Care Pharmacother 2005; 19: 73-78.
97. ADAMS NJ, PLANE MB, FLEMING MF, MUNDT MP, SAUNDERS LA, STAUFFACHER EA. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage 2001; 22: 791-796.
98. FISHMAN SM, KREIS PG. The opioid contract. Clin J Pain 2002; 18: S70-S75.
99. CHOU R, FANCIULLO GJ, FINE PG, ADLER JA, BALLANTYNE JC, DAVIES P, DONOVAN MI, FISHBAIN DA, FOLEY KM, FUDIN J, GILSON AM, KELTER A, MAUSKOP A, O'-CONNOR PG, PASSIK SD, PASTERNAK GW, PORTENOY RK, RICH BA, ROBERTS RG, TODD KH, MIASKOWSKI C; AMERICAN PAIN SOCIETY-AMERICAN ACADEMY OF PAIN MEDICINE OPIOIDS GUIDELINES PANEL. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-130.
100. GATTI A, DAURI M, LEONARDIS F, LONGO G, MARINANGELI F, MAMMUCARI M, SABATO AF. Transdermal buprenorphine in non-oncological moderate-tosevere chronic pain. Clin Drug Investig 2010; 30: 31-38.
101. GATTI A, MAMMUCARI M, SABATO E, MASUCCI L, SABATO AF. Adherence and long-term effect of oxycodone/paracetamol in chronic noncancer pain: A retrospective study. Adv Ther 2011; 28: 418-426.
102. GATTI A, LONGO G, SABATO E, SABATO AF. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. Eur Neurol 2011; 65: 317-322.